Literature DB >> 16130108

Functional recovery after embolic stroke in rodents by activated protein C.

Berislav V Zlokovic1, Chunling Zhang, Dong Liu, Jose Fernandez, John H Griffin, Michael Chopp.   

Abstract

A serine protease activated protein C has been shown to be a powerful neuroprotectant in stressed neurons and in hypoxic brain endothelium. In a clinically relevant model of embolic stroke in rodents, we now show that administration of activated protein C alone or in combination with tissue plasminogen activator, or both, 4 hours after embolic stroke improves the functional outcome and reduces brain infarction within 7 days of stroke. In contrast, tissue plasminogen activator alone was not protective. Thus, activated protein C may be useful as a new stand-alone therapy for clinical stroke and to extend the time window of thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130108     DOI: 10.1002/ana.20602

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

1.  Fingolimod provides long-term protection in rodent models of cerebral ischemia.

Authors:  Ying Wei; Muge Yemisci; Hyung-Hwan Kim; Lai Ming Yung; Hwa Kyoung Shin; Seo-Kyoung Hwang; Shuzhen Guo; Tao Qin; Nafiseh Alsharif; Volker Brinkmann; James K Liao; Eng H Lo; Christian Waeber
Journal:  Ann Neurol       Date:  2010-11-12       Impact factor: 10.422

2.  Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.

Authors:  Yaoming Wang; Meenakshisundaram Thiyagarajan; Nienwen Chow; Itender Singh; Huang Guo; Thomas P Davis; Berislav V Zlokovic
Journal:  Stroke       Date:  2008-12-04       Impact factor: 7.914

Review 3.  Cytoprotective protein C pathways and implications for stroke and neurological disorders.

Authors:  Berislav V Zlokovic; John H Griffin
Journal:  Trends Neurosci       Date:  2011-02-25       Impact factor: 13.837

4.  Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact.

Authors:  Anthony L Petraglia; Andrew H Marky; Corey Walker; Meenakshisundaram Thiyagarajan; Berislav V Zlokovic
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

5.  Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.

Authors:  Yaoming Wang; Zhen Zhao; Nienwen Chow; Tracy Ali; John H Griffin; Berislav V Zlokovic
Journal:  Brain Res       Date:  2013-02-21       Impact factor: 3.252

6.  An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Authors:  Yaoming Wang; Zhenggang Zhang; Nienwen Chow; Thomas P Davis; John H Griffin; Michael Chopp; Berislav V Zlokovic
Journal:  Stroke       Date:  2012-07-17       Impact factor: 7.914

Review 7.  Protein C anticoagulant and cytoprotective pathways.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 8.  Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

Review 9.  Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.

Authors:  Arun Paul Amar; Abhay P Sagare; Zhen Zhao; Yaoming Wang; Amy R Nelson; John H Griffin; Berislav V Zlokovic
Journal:  Neuropharmacology       Date:  2017-09-18       Impact factor: 5.250

10.  Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Authors:  Zhihui Zhong; Hristelina Ilieva; Lee Hallagan; Robert Bell; Itender Singh; Nicole Paquette; Meenakshisundaram Thiyagarajan; Rashid Deane; Jose A Fernandez; Steven Lane; Anna B Zlokovic; Todd Liu; John H Griffin; Nienwen Chow; Francis J Castellino; Konstantin Stojanovic; Don W Cleveland; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.